Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
INSMED Inc (INSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update —Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over t
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The company raised guidance for both BRINSUPRI and ARIKAYCE, received Japan approval and launched BRINSUPRI tablets, and the FDA accepted ARIKAYCE sNDA with Priority Review and a Jan 28, 2027 target action date.
Market read
Traders can update INSM positioning based on raised 2026 revenue guidance and a near-term regulatory catalyst window for ARIKAYCE.
What to watch
The guidance raises are tied to commercial momentum and regulatory progress, but investors may still discount for execution risk in Phase 3 TPIP enrollment and future label-expansion outcomes for ARIKAYCE.
Total Company Revenues of $524.4 Million for the Third Quarter of 2026; BRINSUPRI revenues of $400.1 Million and ARIKAYCE revenues of $124.4 Million.
Total revenues increased 268% to $524.4 million, led by BRINSUPRI revenue of $400.1 million and 29% sequential BRINSUPRI growth. ARIKAYCE revenue increased 9%, the net loss narrowed to $100.3 million from $370.0 million, and the Company raised the low end of 2026 revenue guidance for both commercial products.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenues, net, three months ended September 30GAAP | $524.4M | – | 268% |
| Product revenues, net, nine months ended September 30GAAP | $1.26B | – | 267% |
| ARIKAYCE total revenue, three months ended September 30GAAP | $124.4M | – | 9% |
| ARIKAYCE total revenue, nine months ended September 30GAAP | $338.8M | – | 8% |
| ARIKAYCE U.S. revenue, three months ended September 30GAAP | $75.5M | – | 2% |
| ARIKAYCE international revenue, three months ended September 30GAAP | $48.9M | – | 21% |
| ARIKAYCE U.S. revenue, nine months ended September 30GAAP | $208.6M | – | 1% |
| ARIKAYCE international revenue, nine months ended September 30GAAP | $130.2M | – | 21% |
| BRINSUPRI total revenue, three months ended September 30GAAP | $400.1M | 29% | NM |
| BRINSUPRI total revenue, nine months ended September 30GAAP | $917.1M | – | NM |
| BRINSUPRI U.S. revenue, three months ended September 30GAAP | $398.1M | – | NM |
| BRINSUPRI international revenue, three months ended September 30GAAP | $2M | – | N/A |
| BRINSUPRI U.S. revenue, nine months ended September 30GAAP | $913.8M | – | NM |
| BRINSUPRI international revenue, nine months ended September 30GAAP | $3.3M | – | N/A |
| Total U.S. revenues, three months ended September 30GAAP | $473.6M | – | 364% |
| Total international revenues, three months ended September 30GAAP | $50.8M | – | 26% |
| Total U.S. revenues, nine months ended September 30GAAP | $1.12B | – | 378% |
| Total international revenues, nine months ended September 30GAAP | $133.5M | – | 24% |
| Cost of product revenues (excluding amortization of intangible assets), three months ended September 30GAAP | $78.22M | – | – |
| Cost of product revenues (excluding amortization of intangible assets), nine months ended September 30GAAP | $192.8M | – | – |
| Research and development, three months ended September 30GAAP | $270.0M | – | – |
| Research and development, nine months ended September 30GAAP | $689.5M | – | – |
| Selling, general and administrative, three months ended September 30GAAP | $253.0M | – | – |
| Selling, general and administrative, nine months ended September 30GAAP | $747.8M | – | – |
| Amortization of intangible assets, three months ended September 30GAAP | $5.05M | – | – |
| Amortization of intangible assets, nine months ended September 30GAAP | $9.21M | – | – |
| Change in fair value of contingent consideration liabilities, three months ended September 30GAAP | $7.54M | – | – |
| Change in fair value of contingent consideration liabilities, nine months ended September 30GAAP | −$139.2M | – | – |
| Total operating expenses, three months ended September 30GAAP | $613.8M | – | – |
| Total operating expenses, nine months ended September 30GAAP | $1.50B | – | – |
| Operating loss, three months ended September 30GAAP | −$89.37M | – | – |
| Operating loss, nine months ended September 30GAAP | −$244.2M | – | – |
| Investment income, three months ended September 30GAAP | $11.07M | – | – |
| Interest expense, three months ended September 30GAAP | −$20.41M | – | – |
| Loss before income taxes, three months ended September 30GAAP | −$97.65M | – | – |
| Provision for income taxes, three months ended September 30GAAP | $2.67M | – | – |
| Net loss, three months ended September 30GAAP | −$100.3M | – | – |
| Net loss, nine months ended September 30GAAP | −$277.1M | – | – |
| Basic and diluted net loss per share, three months ended September 30GAAP | $ (0.46 ) | – | – |
| Basic and diluted net loss per share, nine months ended September 30GAAP | $ (1.28 ) | – | – |
| Weighted average basic and diluted common shares outstanding, three months ended September 30GAAP | 218,788 | – | – |
| Weighted average basic and diluted common shares outstanding, nine months ended September 30GAAP | 217,215 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| ARIKAYCE U.S.ARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets. | $75.5M | – | 2% |
| ARIKAYCE InternationalARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets. | $48.9M | – | 21% |
| ARIKAYCE TotalPrimarily driven by strong growth in international markets. | $124.4M | – | 9% |
| BRINSUPRI U.S.BRINSUPRI global revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market. | $398.1M | – | NM |
| BRINSUPRI InternationalBRINSUPRI global revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market. | $2M | – | N/A |
| BRINSUPRI TotalDriven by strong growth in the U.S. market. | $400.1M | 29% | NM |
Full-year 2026 outlook
- NoteBRINSUPRI revenue guidance: $1.35 billion to $1.4 billion
- NoteARIKAYCE revenue guidance: $460 million to $470 million
- NotePeak revenues for BRINSUPRI: more than $7 billion
- NotePeak revenues for TPIP: more than $6 billion
- NotePeak revenues for ARIKAYCE: more than $1 billion
- NoteSubmitting an average of one to two INDs per year from its pre-clinical research programs
- NoteThe totality of its pre-clinical research programs will comprise less than 20% of overall expenditures
What drove it
- BRINSUPRI global revenue grew 29% in the third quarter of 2026 compared to the second quarter of 2026, driven by strong growth in the U.S. market.
- ARIKAYCE global revenue grew 9% in the third quarter of 2026 compared to the third quarter of 2025, primarily driven by strong growth in international markets.
- Cost of product revenues as a percentage of revenues decreased in the third quarter of 2026 due to sales of BRINSUPRI, which has lower manufacturing costs than ARIKAYCE.
- R&D expense increased due to manufacturing costs, clinical development and research costs primarily related to TPIP, and compensation, benefits, and stock-based compensation costs primarily related to higher headcount.
- SG&A expense increased primarily due to professional fees, other external expenses, and compensation and benefit-related expenses driven by BRINSUPRI commercial activities.
- Japan's MHLW approved BRINSUPRI Tablets 25 mg in August 2026, and Insmed launched the product in Japan in October 2026.
- The FDA accepted the ARIKAYCE sNDA for MAC lung disease, granted Priority Review, and set a January 28, 2027 PDUFA target action date.
Concerns
- The Company reported a net loss of $100.3 million for the third quarter of 2026 and a net loss of $277.1 million for the nine months ended September 30, 2026.
- R&D expenses were $270.0 million and SG&A expenses were $253.0 million for the third quarter of 2026 as the Company funds TPIP development and BRINSUPRI commercialization.
- ARIKAYCE U.S. revenue was $75.5 million, up 2% from the third quarter of 2025, while international revenue was $48.9 million, up 21%.
- ARIKAYCE remains subject to an FDA accelerated approval indication in the United States, and the Company is seeking full approval and an expanded label.
- The Company disclosed $544,862 of long-term debt and $146,231 of royalty financing agreement liabilities as of September 30, 2026.
What to watch
- BRINSUPRI commercial execution in the U.S. and Japan following the Japan launch in October 2026.
- FDA action on the ARIKAYCE sNDA for MAC lung disease by the January 28, 2027 PDUFA target action date.
- Planned fourth-quarter 2026 submission of Phase 3 ENCORE data to Japan's PMDA to support a potential ARIKAYCE label expansion.
- PALM-ILD enrollment progress, which exceeded 35% of patients, and the expectation to complete enrollment in the first half of 2028.
- Initiation of the Phase 3 TPIP study in IPF anticipated in the first half of 2027.
- Progression of INS1033, INS1148, INS1201, and INS1202 clinical programs.
Balance sheet and cash flow
- Cash and cash equivalents as of September 30, 2026: $ 396,563
- Marketable securities as of September 30, 2026: $ 750,063
- Cash, cash equivalents, and marketable securities totaling approximately $1.1 billion as of September 30, 2026.
- Accounts receivable as of September 30, 2026: $ 259,270
- Inventory as of September 30, 2026: $ 163,946
- Total assets as of September 30, 2026: $ 2,226,056
- Debt, long-term as of September 30, 2026: $ 544,862
- Current portion of royalty financing agreement as of September 30, 2026: $ 10,232
- Royalty financing agreement as of September 30, 2026: $ 146,231
- Total liabilities as of September 30, 2026: $ 1,499,842
- Total shareholders' equity as of September 30, 2026: $ 726,214
Analysis
Insmed reported a sharp revenue step-up in the third quarter, with product revenues, net of $524.4 million versus $142.3 million in the third quarter of 2025. BRINSUPRI was the principal driver, generating $400.1 million of revenue, including $398.1 million in the U.S. The Company said global BRINSUPRI revenue grew 29% from the second quarter of 2026, driven by strong growth in the U.S. market. ARIKAYCE added $124.4 million of revenue, up 9% from the third quarter of 2025, with international revenue up 21% to $48.9 million and U.S. revenue up 2% to $75.5 million.
The revenue mix supported a substantial improvement in the operating result. Cost of product revenues excluding amortization of intangible assets was $78.2 million, and the Company said cost of product revenues as a percentage of revenues decreased because BRINSUPRI has lower manufacturing costs than ARIKAYCE. Operating loss narrowed to $89.4 million from $366.0 million, while net loss narrowed to $100.3 million, or $0.46 per share, from $370.0 million, or $1.75 per share.
Investment continues to rise alongside commercial expansion and pipeline development. R&D expense was $270.0 million, compared with $186.4 million, reflecting manufacturing costs, clinical development and research costs primarily related to TPIP, and higher headcount-related costs. SG&A expense was $253.0 million, compared with $186.4 million, primarily reflecting professional fees, external expenses, and personnel costs tied to BRINSUPRI commercial activities. The Company held approximately $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2026, while long-term debt was $544.9 million.
Management raised the low end of 2026 guidance for both commercial products. BRINSUPRI guidance is now $1.35 billion to $1.4 billion, from $1.25 billion to $1.4 billion, and ARIKAYCE guidance is now $460 million to $470 million, from $450 million to $470 million. The release also advances the commercial and regulatory agenda: BRINSUPRI launched in Japan in October 2026 after MHLW approval, while the FDA accepted the ARIKAYCE sNDA, granted Priority Review, and set a January 28, 2027 target action date.
Pipeline activity remains broad and spending-intensive. PALM-ILD enrollment exceeded 35%, with completion anticipated in the first half of 2028; PALM-PAH enrolled its first patient in July 2026; and PALM-PPF began in September 2026. Insmed continues to anticipate starting an IPF Phase 3 TPIP study in the first half of 2027. The key operating focus is whether BRINSUPRI growth, ARIKAYCE label expansion, and international commercialization continue to support the raised product revenue ranges while the Company funds multiple late-stage and early-stage programs.
Management, verbatim
The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline.
Will Lewis, Chair and Chief Executive Officer
BRINSUPRI’s U.S. launch continues to exceed expectations and ARIKAYCE continues to grow while in its ninth year on the market. This performance supports our decision to raise the low end of our full-year 2026 revenue guidance for both products.
Will Lewis, Chair and Chief Executive Officer
Not in the filing
stated, not guessed- Gross margin
- Operating margin
- Net loss margin
- Non-GAAP revenue, earnings, operating income, net income, or EPS
- Operating cash flow
- Capital expenditures
- Free cash flow
- Share repurchases
- Dividends
- Quarterly revenue guidance
- Full-year total company revenue guidance
- Gross-margin guidance
- Operating-expense guidance
- Tax-rate guidance
- Prior-quarter values for the consolidated statement of net loss line items
- A separately provided previous outlook section for formal actual-versus-prior-guidance comparisons
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Insmed’s Q3 2026 update covers commercial performance for BRINSUPRI and ARIKAYCE, plus regulatory and Phase 3 progress across its respiratory pipeline.
Ticker impact
Insmed reported Q3 2026 results and raised 2026 BRINSUPRI guidance to $1.35B-$1.4B and ARIKAYCE guidance to $460M-$470M.
Likely upward bias as the market reprices 2026 revenue trajectory and the probability-weighted path to ARIKAYCE label expansion.
The filing includes explicit guidance raises for both commercial products and a concrete regulatory milestone (FDA accepted sNDA with Priority Review and a Jan 28, 2027 PDUFA target), alongside a Japan launch approval and launch timing.
Market effects
Reinforces demand momentum in respiratory specialty biopharma and may lift sentiment for CF/bronchiectasis and MAC-related commercial franchises.
Japan approval and launch expands geographic revenue opportunity and can improve regional growth expectations.
FDA Priority Review and a defined PDUFA target date can affect global comps and risk appetite for respiratory drug developers.
Counterpoint
Revenue growth is strong but the filing also shows much higher R&D and SG&A spend, so margin and cash-flow trajectory may not improve as quickly as top-line guidance.
Key entities
- companyInsmed Incorporated
Nasdaq-listed biopharmaceutical company reporting Q3 2026 results, guidance raises, and regulatory milestones.
- productBRINSUPRI (brensocatib)
Commercial respiratory therapy; Japan approval and launch plus U.S. growth cited.
- productARIKAYCE (amikacin liposome inhalation suspension)
Commercial respiratory therapy; FDA accepted ARIKAYCE sNDA for MAC lung disease with Priority Review.
- regulatorFDA
Accepted Insmed’s ARIKAYCE sNDA and granted Priority Review with a Jan 28, 2027 target action date.
- regulatorJapan MHLW
Approved BRINSUPRI tablets 25 mg for non-cystic fibrosis bronchiectasis in Japan.



